STA wins TGA approval for Iclusig in leukaemia
26 November, 2014 by Dylan Bushell-EmblingSpecialised Therapeutics Australia has secured TGA approval for ARIAD Pharmaceuticals' Iclusig in two types of leukaemia.
New report on medtech industry's global performance
25 November, 2014EY has released its annual medical technology report for 2014 - 'Pulse of the industry: differentiating differently'.
Calzada to divest its Metabolic subsidiary
24 November, 2014 by Dylan Bushell-EmblingCalzada (ASX:CZD) plans to pursue a sale or spin-off of its Metabolic Pharmaceuticals subsidiary to hand over responsibilities for funding the development of peptide fragment AOD9604.
Paradigm BioPharmaceuticals launches $13.5m IPO
24 November, 2014 by Dylan Bushell-EmblingMelbourne's Paradigm BioPharmaceuticals will raise up to $13.5m via an ASX IPO to help raise funds for trials of legacy drug PPS as a treatment for bone marrow edema (BME).
Plans for a joint A/NZ regulator called off
21 November, 2014 by Dylan Bushell-EmblingThe Australian and New Zealand health ministries have mutually cancelled a plan to establish a joint therapeutic products regulator that would replace the TGA and Medsafe.
Consultation opens on guide to China for Australian medtech companies
20 November, 2014AusBiotech and an expert advisory panel have developed a draft 'China Guide' for Australian medtech companies and AusBiotech is now seeking comment.
CSL commences phase IIb heart attack trial
20 November, 2014 by Dylan Bushell-EmblingCSL (ASX:CSL) has launched a trial of CSL112 in patients at risk of recurrent cardiovascular events and presented data into the cholesterol-clearing mechanism of action behind the drug.
Prana's PBT2 generally tolerated in Huntington's trial
19 November, 2014 by Dylan Bushell-EmblingPrana Biotechnology (ASX:PRR) has published results of a trial of its PBT2 candidate in Huntington's disease showing it was generally well tolerated despite some adverse events.
Starpharma to get China patent for Priostar
18 November, 2014 by Dylan Bushell-EmblingStarpharma (ASX:SPL) will receive a Chinese formulation patent covering the use of its Priostar synthetic nanoscale dendrimers in agrochemical applications.
Review of medicines and medical devices regulation commences with forum
18 November, 2014A forum was held last week as the first step in the recently announced independent review of medicines and medical devices regulation. Attendees were advised that the review will commence with a discussion paper, which is expected to be launched by the end of the week, and the opening of the call for submissions.
Next-generation researchers recognised in the AbbVie Student Poster Awards
13 November, 2014The important research being conducted by Australia's graduate students has been featured in a poster display at the recent AusBiotech 2014 national conference, with the most outstanding being recognised with the AbbVie Student Poster Award.
Alchemia CEO leaves as Calzada gets a new one
13 November, 2014 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has announced the sudden departure of CEO Thomas Liquard, Calzada (ASX:CZD) has appointed a new CEO and Patrys (ASX:PAB) has added to its board.
CSL completes $500m placement
13 November, 2014 by Dylan Bushell-EmblingCSL (ASX:CSL) has completed a debt placement worth nearly $500m to help pay for capital management activities including its $900m share buyback.
Govt consults on boosting the commercial returns from research
11 November, 2014A key element of the Industry Innovation and Competitiveness Agenda has begun consultation, with the Australian Government releasing the discussion paper 'Boosting the Commercial Returns from Research'.
Innate commences dosing in SPMS trial
11 November, 2014 by Dylan Bushell-EmblingInnate Immunotherapeutics (ASX:IIL) is dosing patients in a phase IIb trial of its MIS416 candidate in secondary progressive multiple sclerosis, and plans to activate a third site tomorrow.
